Connor, Clark & Lunn Investment Management (CC&L)’s Nektar Therapeutics NKTR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.58M	Sell	36,897 -61,848	-63%	-$4.53M	﹤0.01%	931
2026 Q1	$7.1M	Sell	98,745 -2,421	-2%	-$138K	0.02%	578
2025 Q4	$4.28M	Buy	101,166 +52,549	+108%	+$2.94M	0.01%	696
2025 Q3	$2.77M	Buy	48,617 +27,282	+128%	+$903K	0.01%	753
2025 Q2	$551K	Sell	21,335 -3,219	-13%	-$36.1K	﹤0.01%	1223
2025 Q1	$250K	Sell	24,554 -24,171	-50%	-$316K	﹤0.01%	1291
2024 Q4	$680K	Buy	48,725 +5,336	+12%	+$94.1K	﹤0.01%	1061
2024 Q3	$846K	Buy	43,389 +2,306	+6%	+$44K	﹤0.01%	934
2024 Q2	$764K	Buy	41,083 +2,813	+7%	+$59.3K	﹤0.01%	921
2024 Q1	$536K	Buy	38,270 +5,155	+16%	+$54K	﹤0.01%	1084
2023 Q4	$281K	Buy	33,115 +317	+1%	+$2.4K	﹤0.01%	1190
2023 Q3	$293K	Sell	32,798 -9,513	-22%	-$91.6K	﹤0.01%	1151
2023 Q2	$365K	Buy	42,311 +12,429	+42%	+$133K	﹤0.01%	1063
2023 Q1	$315K	Buy	29,882 +19,127	+178%	+$579K	﹤0.01%	1001
2022 Q4	$365K	Buy	10,755 +10,041	+1,406%	+$486K	﹤0.01%	946
2022 Q3	$34K	Sell	714 -1,808	-72%	-$108K	﹤0.01%	1072
2022 Q2	$144K	Sell	2,522 -8,710	-78%	-$550K	﹤0.01%	961
2022 Q1	$908K	Buy	11,232 +7,692	+217%	+$1.14M	﹤0.01%	681
2021 Q4	$717K	Buy	+3,540	New	+$768K	﹤0.01%	731
2021 Q3	–	Sell	-1,049	Closed	-$270K	–	1163
2021 Q2	$270K	Buy	+1,049	New	+$290K	﹤0.01%	873
2020 Q1	–	Sell	-1,712	Closed	-$554K	–	1119
2019 Q4	$554K	Buy	+1,712	New	+$496K	﹤0.01%	651
2014 Q2	–	Sell	-853	Closed	-$171K	–	603
2014 Q1	$171K	Sell	853 -2,274	-73%	-$450K	﹤0.01%	632
2013 Q4	$566K	Buy	3,127 +2,367	+311%	+$382K	﹤0.01%	468
2013 Q3	$122K	Buy	+760	New	+$141K	﹤0.01%	477

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NKTR Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Nektar Therapeutics (NKTR) stake by 63% in Q2 2026, selling an estimated $4.53M and leaving 36,897 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #931.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NKTR in Q3 2013 and has held it in 24 quarters since. The position peaked at $7.1M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 36,897 shares of Nektar Therapeutics worth $2.58M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 61,848 Nektar Therapeutics shares in Q2 2026, an estimated $4.53M.
Nektar Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #931 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Nektar Therapeutics in Q3 2013 and has held it in 24 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Nektar Therapeutics position peaked at $7.1M in Q1 2026.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.